NEW YORK, NY / ACCESSWIRE / September 7, 2017 / It was a big day for biotech companies Sarepta Therapuetics and Myriad Genetics on Wednesday. Both stocks soared, with Myriad even hitting a new 52-week high after the company introduced riskScore, a tool that can quantify a woman's risk of developing breast cancer by combining genetic markers throughout the genome with her family and clinical history. Shares of Sarepta closed up nearly 14% after a clinical trial revealed positive results on golodirsen, the company's experimental Duchenne muscular dystrophy (DMD) therapy.

RDI Initiates Coverage on:

Sarepta Therapeutics, Inc.
http://www.rdinvesting.com/report/?ticker=SRPT

Myriad Genetics, Inc.
http://www.rdinvesting.com/report/?ticker=MYGN

Sarepta Therapeutics, Inc.'s shares closed up 13.75% yesterday with about 12.3 million shares traded. The big breakout for the company came after traders learned about results from an early-stage muscle biopsy study for Sarepta's experimental Duchenne muscular dystrophy (DMD) therapy, called golodirsen. Golodirsen is for patients whose DMD gene is amenable to skipping exon 53. In the phase 1/2 clinical trial, that had 25 boys with DMD, there was a 100% response rate. Sarpeta said this was "proof of mechanism" for the therapy. The experimental drug is also being studied in a late-stage, placebo-controlled global trial. This trial is expected to enroll about 100 patients and expected to be completed by June 2021.

Access RDI's Sarepta Therapeutics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=SRPT

Myriad Genetics, Inc.'s shares closed up 7.42% on around 2.5 million shares traded on Wednesday. The stock hit a new 52-week high of $33.20 during intra-day trading after the leading molecular diagnostics and personalized medicine company introduced riskScore this week under its myRisk Hereditary Cancer testing portfolio. riskScore is a new clinically validated precision medicine tool to enhance the company's myRisk® Hereditary Cancer test. It quantifies a woman's risk of developing breast cancer by combining genetic markers throughout the genome with her family and clinical history. CEO Mark C. Capone commented, "We have known for some time that there are other genetic and clinical factors that can modify a patient's risk for breast cancer; however, this is the first time that this information has been rigorously validated to guide patient care."

Jerry Lanchbury, Ph.D., Chief Scientific Officer of Myriad Genetics stated, "Having been the leader in every major epoch in hereditary cancer testing, we feel particularly proud of the innovative research employed to develop the riskScore test. The test will actually provide definitive answers for a higher percentage of patients than any previous test and is based upon a rigorous clinical validation. When decisions matter, patients can rely on the quality of Myriad research."

Access RDI's Myriad Genetics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=MYGN

Our Actionable Research on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Myriad Genetics, Inc. (NASDAQ: MYGN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com